SAN FRANCISCO – Novartis has formed an in-house molecular diagnostics unit in order to improve the co-development of companion diagnostics and drugs, a company official told GenomeWeb Daily News today.

The group, co-located in Cambridge, Mass., and Basel, Switzerland, was created in January and should have around 50 to 60 staffers by the end of the year, said Michael Nohaile, head of Novartis Molecular Diagnostics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Nature has retracted a 2002 epigenetics paper for image manipulation.

The World Health Organization calls for the public release of clinical trial results within a year of the completion of data collection.

In Science this week: measles virus nucleocapsid structure, and more.

African and US health officials work to establish an Africa-wide Centres for Disease Control and Prevention.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.